Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/thy.2022.0651 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential markers of cancer stem-like cells in ESCC: a review of the current knowledge.
Front Oncol
January 2024
Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China.
In patients with esophageal squamous cell carcinoma (ESCC), the incidence and mortality rate of ESCC in our country are also higher than those in the rest of the world. Despite advances in the treatment department method, patient survival rates have not obviously improved, which often leads to treatment obstruction and cancer repeat. ESCC has special cells called cancer stem-like cells (CSLCs) with self-renewal and differentiation ability, which reflect the development process and prognosis of cancer.
View Article and Find Full Text PDFRepeat Redifferentiation of Radioiodine Refractory BRAF Mutated Thyroid Cancer with Dabrafenib.
Thyroid
June 2023
Department of Nuclear Medicine, MedStar Washington Hospital Center, Georgetown University Medical Center, Washington, District of Columbia, USA.
Zebrafish hearts can regenerate by replacing damaged tissue with new cardiomyocytes. Although the steps leading up to the proliferation of surviving cardiomyocytes have been extensively studied, little is known about the mechanisms that control proliferation and redifferentiation to a mature state. We found that the cardiac dyad, a structure that regulates calcium handling and excitation-contraction coupling, played a key role in the redifferentiation process.
View Article and Find Full Text PDFCase Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re-differentiation strategy?
Front Nucl Med
January 2023
Nuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.
A 61-year-old woman with a history of metastatic follicular thyroid carcinoma became radioiodine-refractory following two doses of radioiodine (RAI) therapy (cumulative = 230 mCi). While no RAI-avid lesion was noticed in the last post-ablation whole-body radioiodine scan (WBIS), she reported sternal pain, which was accompanied by rapidly rising thyroglobulin levels. F-FDG and Ga-DOTA-TATE PET/CT was performed, showing metastatic pulmonary nodules and a lytic sternal lesion with acceptable avidity (i.
View Article and Find Full Text PDFRedifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Cureus
August 2021
Endocrinology, University of Cincinnati, College of Medicine, Cincinnati, USA.
Radioactive iodine-refractory metastatic differentiated thyroid cancer (RAIR) is associated with a poor prognosis. Multikinase inhibitors have demonstrated improvement in progression-free but not overall survival in such patients, but usage is limited by significant adverse effects and the development of resistance. Clinical research has demonstrated improvement in progression-free survival with the combined use of the BRAF/MEK inhibitor in patients with metastatic melanoma and anaplastic thyroid cancer with the BRAFmutation and has shown promise in redifferentiation of BRAF-positive RAIR differentiated thyroid cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!